# Safety and Efficacy of Ertugliflozin in the Treatment of Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin and Sitagliptin (MK-8835-006; VERTIS SITA2)

> **NCT02036515** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 464 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** Ertugliflozin 5 mg
- **DRUG:** Ertugliflozin 15 mg
- **DRUG:** Placebo for ertugliflozin 5 mg
- **DRUG:** Metformin
- **DRUG:** Sitagliptin
- **DRUG:** Glimepiride
- **BIOLOGICAL:** Insulin
- **DRUG:** Placebo for ertugliflozin 10 mg

## Key facts

- **NCT ID:** NCT02036515
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-03-12
- **Primary completion:** 2016-06-06
- **Final completion:** 2016-06-06
- **Target enrollment:** 464 (ACTUAL)
- **Last updated:** 2018-09-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02036515

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02036515, "Safety and Efficacy of Ertugliflozin in the Treatment of Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin and Sitagliptin (MK-8835-006; VERTIS SITA2)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02036515. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*